Tejera-Hernández AA, Rodríguez-Rodríguez F, Gutiérrez-Giner MI, López-Plasencia Y, Alcalá-Serrano FJ, Hernández-Hernández JR

Language: Spanish
References: 27
Page: 475-480
PDF size: 169.83 Kb.

ABSTRACT

Objective: To analize if parathyroid hormone (PTH) washout levels can be considered a predictive factor of postoperative hypoparathyroidism and determine its importance relative to other features already known as intraoperative PTH, Ca and PTH preoperative, and others. Method: Of the 157 patients to whom a fine needle aspiration (FNA) biopsy with intranodular parathyroid hormone level measurement was performed (washout PTH) 37 who underwent surgery were studied. 15 variables were taken into account when selecting patients for this study: age, gender, evolution length, size, associated thyroid surgery, preoperative treatment with calcimimetics, presence of renal lithiasis, bone densitometry alterations, creatine clearance, preoperative calcium and PTH levels, PTH scores obtained by fine needle aspiration, intraoperative PTH decrease, postoperative calcium levels and tumour malignancy. We compare the nominal values, using the Chi squared or the exact Fisher test, where p ‹ 0.05 was considered statistically significant and perform a logistic regression analysis. Results: The use of calci-mimetics prior to surgery, the preoperative PTH level above 88 pg/dl, the preoperative calcium above 12 mg/dl, washout PTH above 2700 pg/dl, intraoperative PTH level decrease below 15 pg/dl, and postoperative calcium levels under 8.5 mg/dl were all independently significant variables in the univariant analysis (p ‹ 0.05) in order to establish an early postoperative hypoparathyroidism. The rest of the variables were not statistically significative. Conclusion: The PTH washout levels can predict the appearance of postoperative hypoparathyroidism. This factor must be taken into account during the study and follow-up to identify possible complications and establish an adequate treatment on time.

REFERENCES

1. Vélayoudom-Céphise FL, Wémeau JL. Primary hyperparathyroidism and vitamin D deficiency. Ann Endocrinol. 2015;76:153-62.

2. Bancos I, Grant C, Nadeem S, Stan M, Reading C, Sebo T, et al. Risks and benefits of parathyroid fine-needle aspiration with parathyroid hormone washout. Endocr Pract. 2012;18:441-9.

3. Ketha H, Lasho M, Algeciras-Schimnich A. Analytical and clinical validation of parathyroid hormone (PTH) measurement in fine-needle aspiration biopsy (FNAB) washings. Clin Biochem. 2016;49:16-21.

4. Giusti M, Dolcino M, Vera L, Ghiara C, Massaro F, Fazzuoli L, et al. Institutional experience of PTH evaluation on fine-needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. J Zhejiang Univ Sci B. 2009;10:323-30.

5. Stack B, Bimston D, Bodenner D, Brett E, Dralle H, Orloff L, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: postoperative hypoparathyroidism — definitions and management. Endocr Pract. 2015; 21:674-85.

6. Chen Y, Masiakos P, Gaz R, Hodin R, Parangi S, Randolph G, et al. Pediatric thyroidectomy in a high volume thyroid surgery center: risk factors for postoperative hypocalcemia. J Pediatr Surg. 2015;50:1316-9.

7. Lorente-Poch L, Sancho J, Ruiz S, Sitges-Serra A. Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg. 2015;102:359-67.

8. Cusano N, Anderson L, Rubin M, Silva B, Costa A, Irani D, et al. Recovery of parathyroid hormone secretion and function in postoperative hypoparathyroidism: a case series. J Clin Endocrinol Metab. 2013; 98:4285-90.

9. American Thyroid Association Surgery Working Group; American Association of Endocrine Surgeons,; American Academy of Otolaryngology- Head and Neck Surgery; American Head and Neck Society, Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19:1153-8.

10. Walker V, Jan De Beur S. Postoperative hypoparathyroidism: medical and surgical therapeutic options. Thyroid. 2009;19:967-73.

11. Udelsman R, Åkerström G, Biagini C, Duh QY, Miccoli P, Niederle B, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3595-606.

12. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism — risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29:2504-10.

13. Moure MD, Luque-Ramírez M, López G, López M, Gómez-Pan A. Síndrome del hueso hambriento relacionado con hipertiroidismo. An Med Intern. 2006;23:326-8.

14. Rajaei MH, Oltmann SC, Schneider DF, Sippel RS, Chen H. Outcomes after subtotal parathyroidectomy for primary hyperparathyroidism due to hyperplasia: significance of whole vs. partial gland remnant. Ann Surg Oncol. 2015;22:966-71.

15. Merchavy S, Marom T, Forest VI, Hier M, Mlynarek A, McHugh T, et al. Comparison of the incidence of postoperative hypocalcemia following total thyroidectomy vs completion thyroidectomy. Otolaryngol Head Neck Surg. 2015;152:53-6.

16. Hasse C, Sitter H, Brune M, Wollenteit I, Nies C, Rothmund M. Quality of life and patient satisfaction after reoperation for primary hyperparathyroidism: analysis of long-term results. World J Surg. 2002;26:1029-36.

17. Sillero A, Atienza MA. Diagnostic-therapeutic management of parathyroid carcinoma. An Med Intern. 2002;19:644-8.

18. Torun D, Yildiz I, Micozkadioglu H, Nursal GN, Yigit F, Ozelsancak R. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism. Saudi J Kidney Dis Transpl. 2016;27:15-22.

19. Mingione A, Verdelli C, Terranegra A, Soldati L, Corbetta S. Molecular and clinical aspects of the target therapy with the calcimimetic cinacalcet in the treatment of parathyroid tumors. Curr Cancer Drug Targets. 2015;15:563-74.

20. Mercadal G, Blasco I. Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level. Farm Hosp. 2012;36:11-5.

21. Wang J, Gu J, Han Q, Wang W, Shang J. Value of intraoperative parathyroid hormone monitoring in papillary thyroid cancer surgery: can it be used to guide the choice of operation methods? Int J Clin Exp Med. 2015;8:7778-85.

22. Rivere AE, Brooks AJ, Hayek GA, Wang H, Corsetti RL, Fuhrman GM. Parathyroid hormone levels predict posttotal thyroidectomy hypoparathyroidism. Am Surg. 2014;80:817-20.

23. Nilubol N, Weisbrod AB, Weinstein LS, Simonds WF, Jensen RT, Phan GQ, et al. Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy. World J Surg. 2013;37:1966-72.

24. Roshan A, Kamath B, Roberts S, Atkin SL, England RJ. Intra-operative parathyroid hormone monitoring in secondary hyperparathyroidism: is it useful? Clin Otolaryngol. 2006;31:198-203.

25. Rosa KM, Matos LL, Cernea CR, Brandão LG, Araújo VJ. Postoperative calcium levels as a diagnostic measure for hypoparathyroidism after total thyroidectomy. Arch Endocrinol Metab. 2015;21:30.

26. Abdelghani R, Noureldine S, Abbas A, Moroz K, Kandil E. The diagnostic value of parathyroid hormone washout after fine-needle aspiration of suspicious cervical lesions in patients with hyperparathyroidism. Laryngoscope. 2013;123:1310-3.

27. Ing SW, Pelliteri PK. Diagnostic fine-needle aspiration biopsy of an intrathyroidal parathyroid gland and subsequent eucalcemia in a patient with primary hyperparathyroidism. Endocr Pract. 2008;14:80-6.